The role of matrix metalloproteinases in diabetes mellitus

Current Topics in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 1159-1165

  Tsioufis, Costas ^a   Bafakis, Ioannis ^a   Kasiakogias, Alexandros ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Atherosclerosis; Diabetes; Metalloproteinase; Microvascular

Indexed keywords

GELATINASE A; GELATINASE B; IRBESARTAN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PIOGLITAZONE; STROMELYSIN;

ANGIOGENESIS; APOPTOSIS; ARTERIAL STIFFNESS; ARTICLE; BLOOD BRAIN BARRIER; CARDIOVASCULAR RISK; CELL PROLIFERATION; CEREBROVASCULAR DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; GENE TARGETING; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GLYCEMIC CONTROL; HEART LEFT VENTRICLE FUNCTION; HUMAN; MICROALBUMINURIA; MP3 PLAYER; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; RACE; RISK FACTOR; UPREGULATION;

EID: 84861115738     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611208011159     Document Type: Article

References (88)

1. Kannel, W.B.; McGee, D.L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care, 1979, 2, 120-126.
2. Ruderman, N.B.; Haudenschild, C. Diabetes as an atherogenic factor. Prog. Cardiovasc Dis., 1984, 26, 373-412.
3. Haffner, S.M. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr. Rev., 1998, 19, 583-592.
4. King, G.L.; Wakasaki, H. Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. Diabetes Care, 1999, 22, C31-C37.
5. Folli, F.; Corradi, D.; Fanti, P.; Davalli, A.; Paez, A.; Giaccari, A.; Perego, C.; Muscogiuri, G. The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications:Avenues for a Mechanistic-Based Therapeutic Approach. Curr. Diabetes Rev., 2011, 7, 313-324.
6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med., 1993, 329, 977-986.
7. Nagase, H.; Woessner, J.F. Matrix metalloproteinases. J Biol Chem, 1999, 274, 21491-21494.
8. Visse, R.; Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res., 2003, 92, 827-839.
9. Galis, Z.S.; Khatri, J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res., 2002, 90, 251-262.
10. Liu, Y.E.; Wang, M.; Greene, J.; Su, J.; Ullrich, S.; Li, H.; Sheng, S.; Alexander, P.; Sang, Q.A.; Shi, Y.E. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J. Biol. Chem., 1997, 272, 20479-20483.
11. Johnson, C.; Galis, Z.S. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler. Thromb. Vasc Biol., 2004, 24, 54-60.
12. Bruno, G.; Merletti, F.; Biggeri, A.; Bargero, G.; Ferrero, S.; Pagano, G.; Cavallo, Perin P. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care, 2003, 26, 2150-2155.
13. DeFronzo, R.A. In Current Therapy of Diabetes Mellitus; Mosby- Year Book, Inc; Saint Louis; 1998.
14. Feld, LG. Diabetic nephropathy. In: Barratt, T.M., Avner, E.D., editors. Pediatric Nephrology. Lippincott, Williams and Wilkins; Baltimore: 1999.
15. Maxwell, P. Managing diabetic nephropathy. Practitioner, 2005, 249(1666):9-10, 12-4, 16-7.
16. Boright, A.P.; Paterson, A.D.; Mirea, L.; Bull, S.B.; Mowjoodi, A.; Scherer, S.W.; Zinman, B. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes, 2005, 54, 1238-1244.
17. Lelongt, B.; Legallicier, B.; Piedagnel, R.; Ronco, P.M. Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases? Curr. Opin. Nephrol. Hypertens., 2001, 10, 7-12.
18. Lenz, O.; Elliot, S.J.; Stetler-Stevensen, W.G. Matrix metalloproteinases in renal development and disease. J. Am. Soc. Nephrol., 2000, 11, 574-581.
19. Hasegawa, G.; Nakano, K.; Sawada, M.; Uno, K.; Shibayama, Y.; Ienaga, K.; Kondo, M. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int, 1991, 40, 1007-1012.
20. Fowlkes, J.L.; Thrailkill, K.M.; Serra, D.M.; Suzuki, K.; Nagase, H. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Progress in growth factor research. Progr. Growth Factor Res., 1995, 6, 255-263.
21. Ii, M.; Yamamoto, H.; Adachi, Y.; Maruyama, Y.; Shinomura, Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp. Biol. Med. (Maywood), 2006, 231, 20-27.
22. Fowlkes, J.L.; Serra, D.M.; Nagase, H.; Thrailkill, K.M. MMPs are IGFBP-degrading proteinases: implications for cell proliferation and tissue growth. Ann. N.Y. Acad. Sci., 1999, 878, 696-699.
23. Zhuang, S.; Kinsey, G.R.; Rasbach, K.; Schnellmann, R.G. Heparin- binding epidermal growth factor and Src family kinases in proliferation of renal epithelial cells. Am. J. Physiol., 2008, 294, 459-468.
24. Woessner, J.F.; Nagase, H. Matrix Metalloproteinases and TIMPs. 1. New York: Oxford University Press; 2000. Protein substrates of the MMPs; pp. 87-97.
25. Miner, J.H. Renal basement membrane components. Kidney Int., 1999, 56, 2016-2024.
26. Takahara, T.; Furui, K.; Funaki, J.; Nakayama, Y.; Itoh, H.; Miyabayashi, C.; Sato, H.; Seiki, M.; Ooshima, A.; Watanabe, A. Increased expression of matrix metalloproteinase-As in exprimental liver fibrosis in rats. Hepatology, 1995, 21, 787-795.
27. Yang, Q.; Xie, R.J.; Yang, T.; Fang, L.; Han, B.; Zhang, G.Z., Cheng, M.L. Transforming growth factor-beta1 and Smad4 signaling pathway down-regulates renal extracellular matrix degradation in diabetic rats. Chin. Med. Sci. J., 2007, 22, 243-249.
28. Nakamura, T.; Fukui, M.; Ebihara, I.; Osada, S.; Tomino, Y.; Koide H. Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Ren. Physiol. Biochem., 1994, 17, 316-325.
29. Suzuki, D.; Miyazaki, M.; Jinde, K.; Koji, T.; Yagame, M.; Endoh M.; Nomoto, Y.; Sakai, H. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int., 1997, 52, 111-119.
30. Aoyama, T.; Yamamoto, S.; Kanematsu, A.; Ogawa, O.; Tabata, Y. Local delivery of matrix metalloproteinase gene prevents the onset of renal sclerosis in streptozotocin-induced diabetic mice. Tissue Eng., 2003 9 1289-1299.
31. Lauhio, A.; Sorsa, T.; Srinivas, R.; Stenman, M.; Tervahartiala, T.; Stenman, U.H.; Gronhagen-Riska, C.; Honkanen, E. Urinary matrix metalloproteinase -8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in patients with diabetic nephropathy. Ann. Med., 2008, 40, 312-320.
32. Galis, Z.S.; Sukhova, G.K.; Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest., 1994, 94, 493-503.
33. Seifi, M.; Fallah, S.; Firoozrai, M. Influence of genetic polymorphism in matrix metalloproteinase-3 on extent of coronary atherosclerosis and risk of coronary artery stenosis. Arch. Med. Res., 2009, 40(7), 600-604.
34. Westermann, D.; Rutschow, S.; Jäger, S.; Linderer, A.; Anker, S.; Riad, A.; Unger, T.; Schultheiss, H.P.; Pauschinger, M.; Tschöpe, C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes, 2007, 56, 641-646.
35. Van Linthout, S.; Seeland, U.; Riad A.; Eckhardt, O.; Hohl, M.; Dhayat, N.; Richter, U.; Fischer, J.W.; Böhm, M.; Pauschinger, M.; Schultheiss, H.P.; Tschöpe, C. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Diabetes Res. Clin. Pract., 2010, 87, 335-341.
36. Ban, C.R.; Twigg, S.M.; Franjic, B.; Brooks, B.A.; Celermajer, D.; Yue, D.K.; McLennan, SV. Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction. Diabetes Res. Clin. Pract., 2010, 87, 341-356.
37. Derosa, G.; D'Angelo, A.; Scalise, F.; Avanzini, M.A.; Tinelli, C.; Peros, E.; Fogari, E.; Cicero, A.F. Comparison between metalloproteinases- 2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels, 2007, 22, 361-370.
38. Signorelli, S.S.; Malaponte, G.; Libra, M.; Di Pino, L.; Celotta, G.; Bevelacqua, V.; Petrina, M.; Nicotra, G.S.; Indelicato, M.; Navolanic, P.M.; Pennisi, G. Mazzarino MC. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc. Med., 2005, 10, 1-6.
39. Chung, A.W.; Hsiang, Y.N.; Matzke, L.A.; McManus, B.M.; van Breemen, C.; Okon, E.B. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase- 2 and -9 in human type 2 diabetic arterial vasculature. Circ Res, 2006, 99, 140-148.
40. Yasmin, McEniery, C.M.; Wallace, S., Dakham, Z.; Pulsalkar, P.; Maki-Petaja, K.; Ashby, M.J.; Cockcroft, J.R.; Wilkinson, I.B. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb. Vasc. Biol., 2005, 25, 372-378.
41. Chung, A.W.; Hsiang, Y.N.; Matzke, L.A.; McManus, B.M.; van Breemen, C.; Okon, E.B. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ. Res., 2006, 99, 140-148.
42. Chung, A.W.; Yang, H.H.; Sigrist, M.K.; Brin, G.; Chum, E.; Gourlay, W.A.; Levin A. Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease. Cardiovasc Res., 2009, 84, 494-504.
43. Papazafiropoulou, A.; Perrea, D.; Moyssakis, I.; Kokkinos, A.; Katsilambros, N.; Tentolouris, N. Plasma levels of MMP-2, MMP- 9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus. J. Diabetes Complications, 2010, 24, 20-27.
44. Hassan, A.; Markus, HS. Genetics and ischaemic stroke. Brain, 2000, 123, 1784-1812.
45. Markus, H. Genes for stroke. J. Neurol. Neurosurg Psychiatry, 2004, 75, 1229-1231.
46. Brown, D.L.; Hibbs, M.S.; Kearney, M.; Loushin, C.; Isner, J.M. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation, 1995, 91, 2125-2131.
47. Gough, P.J.; Gomez, I.G.; Wille, P.T.; Raines, E.W. Macrophage expression of active MMP-9 induces acute plaque disruption in apo E-deficient mice. J. Clin. Invest., 2006, 116, 59-69.
48. Konstantino, Y.; Nguyen, T.T.; Wolk, R.; Aiello, R.J.; Terra S.G.; Fryburg D.A. Potential imolications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease. Biomarkers, 2009, 14, 118-129.
49. Hawkins, B.T.; Lundeen, T.F.; Norwood, K.M., Brooks, H.L.; Egleton, R.D. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia, 2007, 50, 202-211.
50. Harris, A.K.; Hutchinson, J.R.; Sachidanandam, K.; Johnson, M.H; Dorrance, A.M.; Stepp, D.W.; Fagan, S.C.; Ergul, A. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes, 2005, 54, 2638-2644.
51. Chen, J.; Cui, X.; Zacharek, A.; Cui, Y.; Roberts, C.; Chopp, M. White matter damage and the effect of matrix metalloproteinases in type 2 diabetic mice after stroke. Stroke, 2011, 42, 445-452.
52. Mizutani, M.; Kern, T.S.; Lorenzi, M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J. Clin. Invest., 1996, 97, 2883-2890.
53. Barber, A.J.; Lieth, E.; Khin, S.A.; Antonetti, D.A.; Buchanan, A.G.; Gardner, T.W. Neural apoptosis in the retina during experimental and human diabetes: early onset and effect of insulin. J. Clin. Invest., 1998; 102, 783-791.
54. Kern, T.S.; Tang, J.; Mizutani, M.; Kowluru, R.; Nagraj, R.; Lorenzi, M. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest. Ophthalmol. Vi.s Sci., 2000, 41, 3972-3978.
55. Kowluru, R.A.; Abbas, S.N. Diabetes-induced mitochondrial dysfunction in the retina. Invest. Ophthalmol. Vis. Sci., 2003, 44, 5327-5334.
56. Behl, Y.; Krothapalli, P.; Desta, T.; DiPiazza, A.; Roy, S.; Graves, D.T. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am. J. Pathol., 2008, 172, 1411-1418.
57. Takamura, Y.; Tomomatsu, T.; Kubo, E.; Tsuzuki, S.; Akagi, Y. Role of the polyol pathway in high glucose-induced apoptosis of retinal pericytes and proliferation of endothelial cells. Invest. Ophthalmol. Vis. Sci., 2008, 49, 3216-3223.
58. Kowluru, R.A.; Chan, P.S. Metabolic memory in diabetes - from in vitro oddity to in vivo problem: role of apoptosis. Brain Res. Bull, 2010, 81, 297-302.
59. Joussen, A.M.; Doehmen, S.; Le ML, Koizumi, K.; Radetzky, S.; Krohne, T.U.; Poulaki, V.; Semkova, I.; Kociok, N. TNF- mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis., 2009, 15, 1418-1425.
60. Esteban, L.M.; Vicario-Abejon, C.; Fernandez-Salguero, P.; Fernández-Medarde, A.; Swaminathan, N.; Yienger, K.; Lopez, E.; Malumbres, M.; McKay, R.; Ward, J.M.; Pellicer, A.; Santos, E. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol. Cell Biol., 2001, 21, 1444-1452.
61. Schubbert, S.; Bollag, G.; Shannon, K. Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr. Opin. Genet. Dev., 2007; 17, 15-22.
62. Dufour, A.; Sampson, N.S.; Zucker, S.; Cao, J. Role of the hemopexin domain of matrix metalloproteinases in cell migration. J. Cell Physiol., 2008, 217, 643-651.
63. Yildirim, N.; Sahin, A.; Erol, N.; Kara, S.; Uslu, S.; Topbas S. The relationship between plasma MMP-9 and TIMP-2 levels and intraocular pressure elevation in diabetic patients after intravitreal triamcinolone injection. J. Glaucoma., 2008, 17, 253-256.
64. Jin, M.; Kashiwagi, K.; Iizuka, Y.; Tanaka, Y.; Imai, M,.; Tsukahara, S. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina, 2001, 21, 28-33.
65. Giebel, S.J.; Menicucci, G.; McGuire, P.G.; Das, A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab. Invest., 2005, 85, 567-607.
66. Yang, R.; Liu, H.; Williams, I.; Chaqour, B. Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy. Ann. NY. Acad. Sci., 2007, 1103, 196-201.
67. Das, A.; McLamore, A.; Song, W.; McGuire, P.G. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch. Ophthalmol., 1999, 117, 498-503.
68. Kowluru, R.A.; Kanwar, M. Oxidative stress and the development of diabetic retinopathy: Contributory role of matrix metalloproteinase- 2. Free Rad. Biol. Med., 2009, 46, 1677-1685.
69. Patterson, B.C.; Sang, Q.A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem., 1997, 272, 28823-28825.
70. Soo, C.; Shaw, W.W.; Zhang, X.; Longaker, M.T., Howard, E.W.; Ting, K. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg., 2000, 105, 638-647.
71. Moses, M.A.; Marikovsky, M.; Harper, J.W. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J. Cell Biochem., 1996, 60, 379-386.
72. Baker, E.A.; Leaper, D.J. Profile of matrix metalloproteinases and their tissue inhibitors in intraperitoneal drainage fluid: relationship to wound healing. Wound Rep Reg, 2003, 11, 268-274.
73. Trengove, N.J.; Stacey, M.C.; Macauley, S.; Bennett, N.; Gibson, J.; Burslem, F.; Murphy, G.; Schultz, G. Analysis of the acute and chronic wounds environments: the role of proteases and their inhibitors. Wound Rep. Reg., 1999, 7, 442-452.
74. Wysocki, A.B.; Staiano-Coico, L.; Grinnell, F. Wound fluid from chronic leg ulcers contain elevated levels of metalloproteinases MMP-2 and MMP-9. J. Invest. Dermatol., 1993, 101, 64-68.
75. Yager, D.R.; Zhang, L.Y.; Liang, H.X.; Diegelmann, R.F.; Cohen, I.K. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J. Invest. Dermatol., 1996, 107, 743-748.
76. Yager, D.R.; Stephen, M.C.; Ward, S.I.; Olutoye, O.O.; Diegelmann, R.F.; Cohen, I.K. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Rep. Reg., 1997, 5, 23-32.
77. Nwomeh, B.C.; Liang, H.X.; Cohen, I.K.; Yager, D.R. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J. Surg. Res., 1999, 81, 189-195.
78. Vaalamo, M.; Mattila, L.; Johansson, N.; Kariniemi, A.L.; Karjalainen- Lindsberg, M.L.; Kahari, V.M.; Saarialho-Kere, U. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J. Invest. Dermatol., 1997, 109, 96-101.
79. Bullen, E.C.; Longaker, M.T.; Updike, D.L.; Benton, R.; Ladin, D.; Hou, Z.; Howard, E.W. Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. J. Invest. Dermatol., 1995, 104, 236-240.
80. Vaalamo, M.; Weckroth, M.; Puolakkainen, P.; Kere, J.; Saarinen, P.; Lauharanta, J.; Saarialho-Kere, U.K. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br. J. Dermatol., 1996, 135, 52-59.
81. Ladwig, G.P.; Robson, M.C.; Liu, R.; Kuhn, A.; Muir, D.F.; Schulz, G.S. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Rep. Reg., 2002, 10, 26-37.
82. Lobmann, R.; Schultz, G.; Lehnert, H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care, 2005, 28, 461-471.
83. Trengove, N.J.; Bielefeldt-Ohmann, H.; Stacey, M.C. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Rep Reg, 2000, 8, 13-25.
84. Piaggesi, A.; Viacava, P.; Rizzo, L.; Naccarato, G.; Baccetti, F.; Romanelli, M.; Zampa, V.; Del Prato, S. Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer. Diabetes Care, 2003, 26, 3123-3128.
85. Lobmann, R.; Ambrosch, A.; Schultz, G.; Waldmann, K.; Schiweck, S.; Lehnert, H. Expression of matrix-metalloproteinase and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia., 2002, 45, 1011-1016.
86. McKittrick, I.B.; Bogaert, Y.E.; Nadeau, K.; Snell-Bergeon, J.K.; Hull, A.; Jiang, T.; Wang, X.X.; Levi, M.; Moulton, K.S. Urinary matrix metalloproteinase activities: Biomarkers for plaque angiogenesis and nephropathy in diabetes. Am J Physiol Renal Physiol, 2011, Epub ahead of print. Doi: 10.1152/ajprenal.00267.2011.
87. Fan, X.; Schulz, R. Matrix metalloproteinase-2: an emerging biomarker for reperfusion injury following percutaneous coronary intervention. Heart, 2011. Epub ahead of print. Doi: 10.1136/heartjnl-2011-300886.
88. Zervoudaki, A.; Economou, E.; Pitsavos, C.; Vasiliadou, K.; Aggeli, C.; Tsioufis, C.; Toutouza, M.; Stefanadis, C.; Toutouzas, P. The effects of CA2+ channel antagonists on plasma concentrations of matrix metalloprotease-2 and -9 in essential hypertension Am. J. Hypertens, 2004, 17, 273-276.